Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Ossotide is a multi-component pharmaceutical preparation derived from animal bone extracts, typically sourced from porcine or bovine bones. It is primarily utilized in China for the treatment of bone fractures, osteoarthritis, and rheumatoid arthritis. The preparation is a complex mixture containing polypeptides, various amino acids, and inorganic salts such as calcium and phosphorus. Its therapeutic mechanism involves the promotion of osteoblast proliferation and differentiation, stimulation of collagen and bone matrix protein synthesis, and regulation of bone metabolism. Additionally, it exhibits anti-inflammatory and analgesic properties, which contribute to accelerated fracture healing and improved joint function in patients with degenerative bone diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound ossotide.